Johnson & Johnson Pre-Tax Income 2010-2024 | JNJ
Johnson & Johnson annual/quarterly pre-tax income history and growth rate from 2010 to 2024. Pre-tax income can be defined as company's earnings or loss before taxes on income have been accounted for.
- Johnson & Johnson pre-tax income for the quarter ending September 30, 2024 was $3.338B, a 36.02% decline year-over-year.
- Johnson & Johnson pre-tax income for the twelve months ending September 30, 2024 was $17.626B, a 38.56% increase year-over-year.
- Johnson & Johnson annual pre-tax income for 2023 was $15.062B, a 22.2% decline from 2022.
- Johnson & Johnson annual pre-tax income for 2022 was $19.359B, a 0.94% increase from 2021.
- Johnson & Johnson annual pre-tax income for 2021 was $19.178B, a 16.25% increase from 2020.
Johnson & Johnson Annual Pre-Tax Income
(Millions of US $) |
| 2023 |
$15,062 |
| 2022 |
$19,359 |
| 2021 |
$19,178 |
| 2020 |
$16,497 |
| 2019 |
$17,328 |
| 2018 |
$17,999 |
| 2017 |
$17,673 |
| 2016 |
$19,803 |
| 2015 |
$19,196 |
| 2014 |
$20,563 |
| 2013 |
$15,471 |
| 2012 |
$13,775 |
| 2011 |
$12,361 |
| 2010 |
$16,947 |
| 2009 |
$15,755 |
Johnson & Johnson Quarterly Pre-Tax Income
(Millions of US $) |
| 2024-09-30 |
$3,338 |
| 2024-06-30 |
$5,748 |
| 2024-03-31 |
$3,714 |
| 2023-12-31 |
$4,826 |
| 2023-09-30 |
$5,217 |
| 2023-06-30 |
$6,306 |
| 2023-03-31 |
$-1,287 |
| 2022-12-31 |
$2,485 |
| 2022-09-30 |
$5,172 |
| 2022-06-30 |
$5,840 |
| 2022-03-31 |
$5,862 |
| 2021-12-31 |
$1,238 |
| 2021-09-30 |
$3,849 |
| 2021-06-30 |
$6,662 |
| 2021-03-31 |
$7,429 |
| 2020-12-31 |
$1,647 |
| 2020-09-30 |
$4,401 |
| 2020-06-30 |
$3,940 |
| 2020-03-31 |
$6,509 |
| 2019-12-31 |
$4,218 |
| 2019-09-30 |
$1,647 |
| 2019-06-30 |
$7,041 |
| 2019-03-31 |
$4,422 |
| 2018-12-31 |
$3,122 |
| 2018-09-30 |
$4,423 |
| 2018-06-30 |
$4,973 |
| 2018-03-31 |
$5,481 |
| 2017-12-31 |
$2,560 |
| 2017-09-30 |
$4,790 |
| 2017-06-30 |
$4,748 |
| 2017-03-31 |
$5,575 |
| 2016-12-31 |
$4,324 |
| 2016-09-30 |
$5,281 |
| 2016-06-30 |
$4,904 |
| 2016-03-31 |
$5,294 |
| 2015-12-31 |
$3,758 |
| 2015-09-30 |
$4,122 |
| 2015-06-30 |
$5,741 |
| 2015-03-31 |
$5,575 |
| 2014-12-31 |
$2,703 |
| 2014-09-30 |
$6,810 |
| 2014-06-30 |
$5,626 |
| 2014-03-31 |
$5,424 |
| 2013-12-31 |
$2,750 |
| 2013-09-30 |
$3,667 |
| 2013-06-30 |
$4,793 |
| 2013-03-31 |
$4,261 |
| 2012-12-31 |
$3,100 |
| 2012-09-30 |
$3,595 |
| 2012-06-30 |
$2,035 |
| 2012-03-31 |
$5,045 |
| 2011-12-31 |
$318 |
| 2011-09-30 |
$4,111 |
| 2011-06-30 |
$3,422 |
| 2011-03-31 |
$4,510 |
| 2010-12-31 |
$2,228 |
| 2010-09-30 |
$4,219 |
| 2010-06-30 |
$4,220 |
| 2010-03-31 |
$6,280 |
| 2009-12-31 |
$2,604 |
| 2009-09-30 |
$4,245 |
| 2009-06-30 |
$4,263 |
| 2009-03-31 |
$4,643 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$373.591B |
$85.159B |
|
Johnson & Johnson's biggest strength is its diversified business model. It operates through pharmaceuticals, medical devices and consumer products divisions. Its diversification helps it to withstand economic cycles more effectively. J&J has one of the largest research and development (R&D) budget among pharma companies. J&J's worldwide business is divided into three segments: Pharmaceutical, Medical Devices and Consumer. The company has several drugs covering a broad range of areas such as neuroscience, cardiovascular & metabolism, immunology, oncology, pulmonary hypertension and infectious diseases and vaccines. The Medical Devices Segment offers products in the orthopedics, surgery, interventional solutions and vision markets. The Consumer Segment segment includes a broad range of products covering the areas of baby care, beauty/skin health, oral care, wound care and womens' health care, as well as over-the-counter (OTC) pharmaceutical products.
|
